Treatment with xalnesiran, a small interfering RNA molecule, plus an immunomodulator resulted in hepatitis B surface antigen loss among adults with chronic HBV infection, according to a study ...

Researchers update clinical practice guidelines for how to prevent and monitor hepatitis B virus reactivation.

Brelovitug is designed to neutralize and remove hepatitis B and hepatitis D virions and deplete HBsAg-containing subviral particles, which makes brelovitug a potentially safe and highly efficacious ...

A functional cure is said to have been achieved if HBsAg is cleared from the blood and remains undetectable after stopping all treatment. In B-Clear, patients with low baseline HBsAg levels ...

Despite numerous treatment advances ... and hepatitis B s antigen (HBsAg), which is HBV’s envelope protein. In addition to the excess HBsAg present in circulating virions, large amounts of ...

The primary efficacy end point was HBsAg loss at 24 weeks after the end of treatment. The researchers found that a primary end point event occurred in 7, 3, 12, 23, and 0 percent of patients in ...

This is seen as a significant step forward in targeting HBsAg, a crucial antigen in hepatitis B treatment. Dr. Leon Hooftman, Chief Medical Officer of Barinthus Bio, remarked, “These data ...

At 72 weeks, IHCs in the treatment group were categorized into an HBsAg clearance group and an HBsAg persistence group. Differences in T lymphocyte subsets among these groups were compared ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).

Assays for hepatitis B surface antigen (HBsAg) are the most frequently used tests to detect HBV infection. Vaccination for HBV can produce transiently detectable levels of HBsAg in patients.